Mereo BioPharma Group PLC

NASDAQ:MREOUnited States

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Contact Information

Headquarters

One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF

Phone

---

Fax

---

Executives

Non-Executive Independent Director

Michael Wyzga

Chief Executive Officer, Director

Denise Scots-Knight

Chief Financial Officer

Christine Fox

Senior Vice President - Clinical Development

Suba Krishnan

Senior Vice President - Therapeutic Head

Jackie Parkin